

ICH Q4B Expert Working Group

International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use



Presentation Outline

- Short History and Overview of ICH Q4B
- The Pharmacopoeias and the Regulators
- The Q4B Process and Annex
- Interaction: Q4B Expert Working Group (EWG) and PDG
- November 2008 Meeting Outcomes and Current Activities for the Q4B EWG

Background

- The harmonisation of specific compendial test chapters has been considered as critical by the ICH Steering Committee to attaining full utility of the ICH Q6A guideline (1998).
- Industry requested ICH SC to create an EWG to address how the regulatory authorities (3 regions) will recognise the interchangeability of harmonised pharmacopoeial chapters from Ph. Eur./JP/USP (PDG) – July 2003
- ICH SC established Q4 EWG with a scope to address 11 General Test Chapters discussed during development of ICH Q6A Guideline - November 2003
- SC approves Q4B Work Plan – April 2004

Background (Continued)

- SC approves development of an ICH Guideline with topic specific annexes – June 2004
- Q4B EWG begins evaluating PDG harmonised text – November 2004
- Step 2 ICH Q4B Core Guideline approved by SC – June 2006
- 1st Annex (Residue on Ignition/Sulphated Ash) approved (ICH Step 2) – June 2006
- Regulatory consultation (ICH Step 3) on Core Guideline completed by each regulatory region (60-day comment period) – October 2006

Background (Continued)

- Core Q4B Guideline reworked based on constituent comments; ICH Step 4 documents finalised for ICH signoff – November 2007
- Consist of “parent guideline” Step 4 Q4B – ERPTUIR (new title)
- “Evaluation and Recommendation Pharmacopoeial Texts for Use in the ICH regions”
- First Annex No. 1 approved at Step 4 – ROI/Sulphated Ash – November 2007
- SC approves limited expansion of scope – November 2008

ICH Q6A-related General Chapters

Dissolution

*Uniformity of Content

Extractable Volume

Sterility

Bacterial Endotoxins

Colour and Clarity

(per ICH SC, work will just be on "Colour")

Disintegration

*Uniformity of Mass

Particulate Matter

Microbiological Quality


ROI/Sulphated Ash

Above chapters identified as the basis of Q4B activity

* Combined to Uniformity of Dosage Units

The Pharmacopoeias and the Regulators

Different Approaches for Moving Forward



JP
(PMDA)

Governmental



Ph. Eur.
(EDQM)

Governmental
Partnership



USP

Independent of
Government
Not for profit organisation

The Q4B Process

Value of the Q4B Activity

- A component of international harmonisation efforts to assist in common specifications
 - A savings in time, effort and cost
 - Industry: to globally unify testing strategies [for applications and other regulatory (compliance) needs] – one test rather than three
 - Regulators: to reduce or eliminate the need to go through a justification procedure as to the use of other compendial methods (done one time to eliminate repetitive justifications)
-

PDG Process Results in Harmonised Text

Individual Pharmacopoeial Approval & Official Publication Process

JP Version

USP Version

Ph. Eur. Version

Challenge to regulators: Do differences impact on the ability to achieve a result with the same accept and reject capability? Are they interchangeable?

Q4B Process Steps


FOR EACH TOPIC:

- PDG provides to Q4B Expert Working Group:
 - PDG-harmonised text
 - JP/Ph. Eur./USP draft versions of how harmonised text will be implemented in their compendia
 - Briefing note to delineate any local differences or potential issues
 - Printing timelines to move approved pharmacopoeial text to official status
- Q4B member parties bring the documents back to their constituents for independent evaluation

Q4B Process (continued)

- Q4B EWG reviews the evaluations
- Issues discussed within Q4B EWG for possible resolution
- Evaluation results and possible resolution mechanisms conveyed back to and/or discussed with PDG
- Once issues are resolved, Q4B EWG recommends approval (ICH Step 2) to the ICH SC
- Start of Annex process – Moving the Q4B evaluation outcome into the regulatory mechanisms for each region

Topic Specific Annex Process



Q4B EWG and PDG Interaction

- Dedicated time (set aside) at each formal ICH EWG meeting venue to discuss issues
- Stakeholder partnering – all parties focused to achieve interchangeability
- Direct feedback mechanisms to resolve issues
- Clear delineation of what steps are necessary for problem resolution
- Success more likely versus single, independent efforts

Q4B Successes -- November 2007 Yokohama

Primary objectives achieved:

- Core Q4B Guideline (establishing Q4B Process)
Completed and signed off at ICH Step 4 -- Step 5 Regional Implementation
- Title for the Q4B Core Q4B Guideline
***The Evaluation and Recommendation
of
Pharmacopoeial Texts for Use in the ICH Regions***
- First Annex No.1 – ROI/Sulphated Ash completed
at Step 4

Current Status – Q4B EWG

ICH November 2008, Brussels

- Step 2 documents moved to Step 4 sign-off and Step 5 Regional Implementation:
 - (Annexes 4A, 4B, 4C)
 - (Annex 5 – completed but hold for sign-off)
- Additional annexes moved to Step 2 sign-off:
 - Annex 6 UDU
 - Annex 7 Dissolution Test
 - Annex 8 Sterility Test

Limited Scope Expansion

ICH November 2008, Brussels

Steering Committee approved addition of 5 new PDG-harmonised general chapters to the Q4B process:

1. Tablet Friability
2. Bulk and tapped density
3. Analytical Sieving
4. Capillary Electrophoresis
5. PAGE

Current Status – Q4B EWG

ICH November 2008 Meeting, Brussels, Belgium

Completed Annexes to the Core Q4B Guideline

■ #1 Residue on Ignition/Sulphated Ash

**Step 5 Regional
Implementation**

■ #2 Extractable Volume

**Step 5 Regional
Implementation**

■ #3 Particulate Matter

**Step 5 Regional
Implementation**

■ #4A, 4B, 4C Microbiological Tests

**Step 5 Regional
Implementation**

Current Status 2009 (continued)

Work in Progress

- #5 Disintegration TestDraft Step 4, waiting to be signed [Spring 2009]
 - #6 Dissolution Test
 - #7 Uniformity of Dosage Units
 - #8 Sterility Test
 - Bacterial Endotoxins
 - Colour
- Signed at Step 2 – Regulatory Consultation (ICH Step 3)
- Submissions awaited from PDG
-

Acknowledgements

Robert King, FDA – 1st Rapporteur and all Q4B members
PDG member pharmacopoeias and their continuing support !

Current Members of the ICH Q4B EWG

Cindy Buhse (FDA)
Nick Cappuccino (IGPA)
Jon Clark (FDA)
G rard Damien (EFPIA)
Martine Draguet (EFPIA)
Nobukazu Igoshi (JPMA)
Robert King (FDA)
Sabine Kopp (WHO)
Carmen de la Morena-Criado (EU)
Osamu Morita (MHLW)
J.M. Morris (EU)

Tsuneo Okubo (JPMA)
St phanie Parra (Health Canada)
Janos Pogany (WHO)
Hideki Sasaki (JPMA)
Janeen Skutnik (PhRMA)
Koumei Shimokawa (MHLW)
Toyashige Tanabe (JPMA)
Kiyomi Ueno (MHLW)
Petar Vojvodic (WSMI)
Kiyoshi Washida (JPMA)
J. Mark Wiggins (PhRMA)